Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

December 21st 2023

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer

December 15th 2023

The FDA has approved enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

December 15th 2023

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

December 14th 2023

The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF TKI.

Ide-Cel Wins Japanese Approval in Early Relapsed/Refractory Multiple Myeloma

December 14th 2023

Idecabtagene vicleucel has received marketing and manufacturing approval in Japan for its supplemental new drug application in patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy.

FDA Grants Priority Review to Tarlatamab for Small Cell Lung Cancer

December 14th 2023

The FDA has accepted and granted priority review to the biologics license application seeking the approval of tarlatamab for the treatment of patients with advanced small cell lung cancer.

DZD8586 Demonstrates Responses Across Dose Levels in B-Cell Non-Hodgkin Lymphoma

December 13th 2023

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

December 13th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

December 12th 2023

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed

December 12th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

December 11th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL

December 10th 2023

Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.

Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies

December 10th 2023

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy in younger and older patients with hematologic malignancies, according to data from a phase 1b study.

All-Oral Arsenic Trioxide, All-Trans Retinoic Acid/Ascorbic Acid Proves Effective, Safe in Acute Promyelocytic Leukemia

December 9th 2023

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC

December 8th 2023

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Nivolumab Plus Ipilimumab Improves PFS in Newly Diagnosed Metastatic Colorectal Cancer

December 7th 2023

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

December 1st 2023

The FDA has granted an accelerated approval to pirtobrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

FDA Grants Priority Review to sBLA for Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

December 1st 2023

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin plus pembrolizumab for the frontline treatment of patients with locally advanced or metastatic urothelial cancer.

FDA Grants Fast Track Designation to Zotatifin Plus Fulvestrant/Abemaciclib in ER+/HER2– Breast Cancer

November 30th 2023

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

Nadofaragene Firadenovec Induces Durable Activity in High-Risk, BCG-Unresponsive NMIBC With CIS

November 29th 2023

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

NEXT PAGE
PREVIOUS PAGE